Skip to main content
. 2019 Jul 14;11(7):983. doi: 10.3390/cancers11070983

Figure 3.

Figure 3

Overview of the gene selection process in tumor specimens containing AMER1, SOX9, ACVR2A and ANK3 mutations. For each mutation, only the top 50 (or if less, all) upregulated genes were utilized in the subsequent survival analyses. The genes associated with worse survival were assessed for potential druggability, and the ultimately selected genes were validated in a clinical sample.